Price effects of a hospital merger: Heterogeneity across health insurers, hospital products, and hospital locations.


Journal

Health economics
ISSN: 1099-1050
Titre abrégé: Health Econ
Pays: England
ID NLM: 9306780

Informations de publication

Date de publication:
09 2019
Historique:
received: 13 07 2018
revised: 26 03 2019
accepted: 19 05 2019
pubmed: 3 7 2019
medline: 11 8 2020
entrez: 3 7 2019
Statut: ppublish

Résumé

In most studies on hospital merger effects, the unit of observation is the merged hospital, whereas the observed price is the weighted average across hospital products and across payers. However, little is known about whether price effects vary between hospital locations, products, and payers. We expand existing bargaining models to allow for heterogeneous price effects and use a difference-in-differences model in which price changes at the merging hospitals are compared with price changes at comparison hospitals. We find evidence of heterogeneous price effects across health insurers, hospital products and hospital locations. These findings have implications for ex ante merger scrutiny.

Identifiants

pubmed: 31264329
doi: 10.1002/hec.3920
pmc: PMC6772112
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1130-1145

Subventions

Organisme : Dutch Healthcare Authority
Pays : International

Informations de copyright

© 2019 The Authors Health Economics Published by John Wiley & Sons Ltd.

Références

N Engl J Med. 2014 Oct 30;371(18):1704-14
pubmed: 25354104
Health Econ. 2019 Sep;28(9):1130-1145
pubmed: 31264329
Health Econ Policy Law. 2007 Jan;2(Pt 1):51-71
pubmed: 18634671
Synth Proj Res Synth Rep. 2006 Feb;(9):
pubmed: 22051574
J Health Econ. 2001 Sep;20(5):733-53
pubmed: 11558646
Health Econ. 2005 Sep;14(Suppl 1):S59-74
pubmed: 16161190
Health Econ Rev. 2014 Dec;4(1):28
pubmed: 26208928
J Health Polit Policy Law. 1994 Summer;19(2):423-47
pubmed: 8077637
Health Aff (Millwood). 2006 Sep-Oct;25(5):w337-43
pubmed: 16868008
Health Aff (Millwood). 2011 Jan;30(1):51-61
pubmed: 21209437
Eur J Health Econ. 2011 Dec;12(6):589-603
pubmed: 20853127
N Engl J Med. 2013 Aug 29;369(9):789-91
pubmed: 23944255
N Engl J Med. 2009 Jul 9;361(2):109-12
pubmed: 19494209
Rand J Econ. 2003 Winter;34(4):737-63
pubmed: 14992231
Rand J Econ. 2003 Winter;34(4):764-85
pubmed: 14992232

Auteurs

Anne-Fleur Roos (AF)

Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, Netherlands.

Ramsis R Croes (RR)

Erasmus School of Health Policy & Management, Erasmus University Rotterdam & Dutch Healthcare Authority, Utrecht, Netherlands.
Dutch Healthcare Authority, Utrecht, Netherlands.

Victoria Shestalova (V)

Dutch Healthcare Authority, Utrecht, Netherlands.

Marco Varkevisser (M)

Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, Netherlands.

Frederik T Schut (FT)

Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH